

Highlights of This Issue 2919

SPECIAL FEATURES

CCR New Strategies

- 2921 **New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer**
Hans Prenen, Sabine Tejpar, and Eric Van Cutsem

Molecular Pathways

- 2927 **CXCL12 (SDF-1)/CXCR4 Pathway in Cancer**
Beverly A. Teicher and Simon P. Fricker
- 2932 **Control of Tumorigenesis and Chemoresistance by the DEK Oncogene**
Erica Riveiro-Falkenbach and María S. Soengas

HUMAN CANCER BIOLOGY

- 2939 **The Proapoptotic Molecule BLID Interacts with Bcl-X_L and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival**
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seillier-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid
- 2949 **The Tumor Suppressor UCHL1 Forms a Complex with p53/MDM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma**
Lili Li, Qian Tao, Hongchuan Jin, Andrew van Hasselt, Fan Fong Poon, Xian Wang, Mu-Sheng Zeng, Wei-Hua Jia, Yi-Xin Zeng, Anthony T.C. Chan, and Ya Cao

- 2959 **The Transcriptional Coregulator RIP140 Represses E2F1 Activity and Discriminates Breast Cancer Subtypes**
Aurélie Docquier, Pierre-Olivier Harmand, Samuel Fritsch, Maïa Chanrion, Jean-Marie Darbon, and Vincent Cavaillès
- 2971 **Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q- Neuroblastoma**
Patrick G. Buckley, Leah Alcock, Kenneth Bryan, Isabella Bray, Johannes H. Schulte, Alexander Schramm, Angelika Eggert, Pieter Mestdagh, Katleen De Preter, Jo Vandesompele, Frank Speleman, and Raymond L. Stallings
- 2979 **Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis**
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzeri, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

CANCER THERAPY: PRECLINICAL

- 2989 **Assessment of the *In vivo* Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models**
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebrook, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt
- 2999 **Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer**
Gloria S. Huang, Jurriaan Brouwer-Visser, Marissa J. Ramirez, Christine H. Kim, Tiffany M. Hebert, Juan Lin, Hugo Arias-Pulido, Clifford R. Qualls, Eric R. Prossnitz, Gary L. Goldberg, Harriet O. Smith, and Susan Band Horwitz

IMAGING, DIAGNOSIS, PROGNOSIS

- 3011 **Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer**
Tahlita C.M. Zuiverloon,
Madelon N.M. van der Aa,
Theo H. van der Kwast, Ewout W. Steyerberg,
Hester F. Lingsma, Chris H. Bangma,
and Ellen C. Zwarthoff

CANCER THERAPY: CLINICAL

- 3019 **A Phase I Study of 5-Fluorouracil/Leucovorin and Arsenic Trioxide for Patients with Refractory/Relapsed Colorectal Carcinoma**
Bach Ardalan, Pochi R. Subbarayan,
Yipsel Ramos, Michael Gonzalez,
Anthony Fernandez, Dmitry Mezentsev,
Isildinha Reis, Robert Duncan,
Lisa Podolsky, Kelvin Lee, Mayra Lima,
and Parvin Ganjei-Azar
- 3028 **Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer**
Tanya B. Dorff, Bryan Goldman,
Jacek K. Pinski, Philip C. Mack,
Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr.,
David I. Quinn, Nicholas J. Vogelzang,
Ian M. Thompson, Jr., and Maha H.A. Hussain
- 3035 **Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors**
Petri Nokisalmi, Sari Pesonen,
Sophie Escutenaire, Merja Särkioja,
Mari Raki, Vincenzo Cerullo,
Leena Laasonen, Ramon Alemany,
Juan Rojas, Manel Cascallo, Kilian Guse,
Maria Rajeci, Lotta Kangasniemi,
Elina Haavisto, Aila Karioja-Kallio,
Päivi Hannuksela, Minna Oksanen,
Anna Kanerva, Timo Joensuu,
Laura Ahtiainen, and Akseli Hemminki

- 3044 **Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors**
Alain C. Mita, Chris H. Takimoto,
Monica Mita, Anthony Tolcher,
Kamalesh Sankhala, John Sarantopoulos,
Manuel Valdivieso, Leslie Wood,
Erik Rasmussen, Yu-Nien Sun,
Z. Don Zhong, Michael B. Bass,
NgocDiep Le, and Patricia LoRusso


- 3057 **A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer**
Andrew J. Armstrong, George J. Netto,
Michelle A. Rudek, Susan Halabi,
David P. Wood, Patricia A. Creel, Kelly Mundy,
S. Lindsay Davis, Ting Wang,
Roula Albadine, Luciana Schultz,
Alan W. Partin, Antonio Jimeno, Helen Fedor,
Phillip G. Febbo, Daniel J. George,
Robin Gurganus, Angelo M. De Marzo,
and Michael A. Carducci

- 3067 **Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers**
Kevin J. Harrington,
Eleni M. Karapanagiotou,
Victoria Roulstone, Katie R. Twigger,
Christine L. White, Laura Vidal,
Debbie Beirne, Robin Prestwich,
Kate Newbold, Merina Ahmed, Khin Thway,
Christopher M. Nutting, Matt Coffey,
Dean Harris, Richard G. Vile,
Hardev S. Pandha, Johann S. DeBono,
and Alan A. Melcher

- 3078 **A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non-Small Cell Lung Cancer**
Joline S.W. Lind, Anne-Marie C. Dingemans,
Harry J.M. Groen, Frederik B. Thunnissen,
Otto Bekers, Daniëlle A.M. Heideman,
Richard J. Honeywell, Elisa Giovannetti,
Godefridus J. Peters, Pieter E. Postmus,
Robert Jan van Suylen, and Egbert F. Smit

ABOUT THE COVER

BLID expression was found to be lost or decreased in several invasive ductal breast carcinomas (IDC). The cover image shows an example of BLID-negative IDC as determined by immunohistochemistry using a breast tumor tissue microarray. Lack of BLID was associated with poor prognostic factors and survival. For details, see the article by Broustas and colleagues on page 2939 of this issue.



Clinical Cancer Research

16 (11)

Clin Cancer Res 2010;16:2919-3087.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/16/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/16/11>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.